Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

DTC ad oversight by FDA should include corrective ad campaigns, consumer rep suggests.

This article was originally published in The Tan Sheet

Executive Summary

DTC AD OVERSIGHT OF CORRECTIVE CAMPAIGNS SUGGESTED BY CONSUMER REP on the basis that FDA's current program does not ensure patients receive balanced information if a campaign is found to be misleading, National Women's Health Network Exec Director Cynthia Pearson told an agency "stakeholders" meeting Aug. 17. "If the FDA directs companies to revise an ad campaign or orders the ad pulled, consumers have no way of knowing that. An entire nation of magazine readers and TV viewers have seen the ad and the damage has already been done," Pearson asserted.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088772

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel